After years of hard work and dedication, I'm blessed to say that I have successfully passed Board exam for the European Society for Medical Oncology #ESMO examination 2024 as well.
Replying to @myESMO
@myESMO 2026: Top trending breast cancer oncologists on ๐.
Explore #ESMO26 insights here: clin.larvol.com/conference/aโฆ
#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BreastCancer #TNBC #BCSM #ClinicalOncology | @PTarantinoMD | @dr_yakupergun | @ErikaHamilton9 | @MamMa_mimumemo | @barriere_dr | @Dr_Oncologista | @stolaney1 | @shimoi_oncology | @drsarahsam | @NeilVasan | @DrSGraff | @DrBarbiOnc | @hoperugo | @Dr_ElvinaA | @to_be_elizabeth
Replying to @myESMO
@myESMO 2026: Most discussed breast cancer trials by influencer posts on ๐.
Explore #ESMO26 insights here: clin.larvol.com/conference/aโฆ
#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BreastCancer #TNBC #BCSM #ClinicalOncology | @dr_yakupergun | @PTarantinoMD | @MamMa_mimumemo | @Dr_Oncologista | @ErikaHamilton9 | @DrSGraff | @stolaney1 | @ElisaAgostinett | @matteolambe | @E_de_Azambuja
Aya Mohamed | MSc, MD ๐ retweeted
OUT TODAY!!
THE COMPLETE #ESMO26 NEWSLETTER ๐ฐ
Bringing together our top picks from the most important trials presented in Madrid, all in one email.
๐ฉ Register to receive it: buff.ly/N5gYtAc
Curated by oncologists, for colleagues in cancer care, our mission is to make the latest oncology science accessible, relevant, and easy to digest.
We are OncoAlert ๐จ โ For Colleagues, by Colleagues.
Best,
The OncoAlert Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
๐ค Made with AI
Aya Mohamed | MSc, MD ๐ retweeted
Thank you Colleagues for a phenomenal #ESMO26
ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. ๐ OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME.
๐ฃ 101.7M impressions of potential reach
๐ฌ 6.1K posts on X from 988 participants in 34 countries
โก 43.1 posts per hour across the meeting days
๐ 45% positive sentiment, with only 6% negative
Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO
๐ Top influencers
@DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista
๐ Where the conversation came from
North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities.
๐ฌ Top studies by impact
1๏ธโฃ DeLLphi-305 (SCLC): 4.0M reach, 170 posts
2๏ธโฃ VOLGA (bladder): 3.7M reach, 141 posts
3๏ธโฃ KRASCENDO-1 (NSCLC): 3.5M reach
4๏ธโฃ SAFFRON (NSCLC): 3.3M reach
5๏ธโฃ INTerpath-001 (melanoma): 154 posts
Pinging our Collaborators
Aya Mohamed | MSc, MD ๐ retweeted
TroFuse-005, investigational: โThat is clinically meaningful and warrants use.โ โThe tox is a concern.โ โ @DrKatyMoore
KEYNOTE-C93 (@Merck): โImportant caveat: Comparator was chemotherapy alone, NOT the current chemo-immunotherapy standard.โ โ @SuyogCancer
hubs.ly/Q04CnqTR0
Aya Mohamed | MSc, MD ๐ retweeted
BFv Showed Activity in Pretreated Metastatic Triple-Negative Breast Cancer After Prior Top1i-ADC Exposure - Aya Mohamed
@Dr_Oncologista
oncodaily.com/science/aya-moโฆ
Aya Mohamed | MSc, MD ๐ retweeted
Dear colleagues,
We are already curating THE COMPLETE #ESMO26 NEWSLETTER ๐ฐ our picks of the top trials presented in Madrid, together in one email.
Register to receive it ๐ buff.ly/N5gYtAc
Every newsletter is curated by oncologists, for colleagues working in cancer care. Itโs our way of making science quick and accessible.
We are OncoAlert๐จ For Colleagues, by Colleagues
Best,
The Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
Aya Mohamed | MSc, MD ๐ retweeted
Day 1 of #ESMO26 ๐ป๐
Following the latest in oncology. ๐งฌ
@OncoAlert
ASTRIDE:๐ซ
Serplulimab + chemotherapy showed a numerical OS advantage over atezolizumab + chemotherapy in 1L ES-SCLC (12.4 vs 10.2 months; HR 0.82).
@OncoAlert #ESMO26 #LungCancer #ESMOAmbassadors #Lcsm #ESMOcommunity @myESMO
DeLLphi-304: ๐ซ
Tarlatamab sustained its OS benefit at 23-month follow-up, improving median OS to 13.6 vs 8.4 months (HR 0.62)
@OncoAlert #ESMO26 @ESMO_Open #ESMOAmbassadors #LungCancer #ESMOcommunity @myESMO
๐ข #ESMO26 concomitant paper: Extended follow-up of #tarlatamab in patients with small-cell lung cancer after platinum-based chemo in the phase 3 DeLLphi-304 study.
๐shorturl.at/QFAwC
@JulienMazieres @pedrofrocha @UniklinikEssen @medizinischefakultaet @g_mountzios
OptiTROP-Breast01:
Sac-TMT improved median OS in pretreated mTNBC (14.7 vs 9.9 months; HR 0.60), reinforcing the role of ADCs in later-line treatment.
@OncoAlert #ESMO26 #ESMOAmbassadors #ESMOcommunity @myESMO #BreastCancer #bcsm
DESTINY-Breast09: #ESMO26
T-DXd + pertuzumab showed encouraging systemic and intracranial activity in 1L HER2+ mBC with baseline brain metastases, with CNS-PFS HR 0.26 vs THP.
@OncoAlert #BreastCancer #bcsm #ESMOAmbassadors #ESMOcommunity @myESMO
INSPIRE-LM:
In HER2+ leptomeningeal metastases, radiotherapy followed by intrathecal trastuzumab/pertuzumab showed a median OS of 36.2 months and median LM-PFS of 19.3 months.
@OncoAlert #BreastCancer #ESMO26 #ESMOAmbassadors #BCSM #ESMOcommunity @myESMO
HER2-CR: Persistent ctDNA negativity may help identify long-term responders with HER2+ MBC who could be candidates for anti-HER2 treatment discontinuation.
Prospective validation is essential before using ctDNA to guide treatment cessation.
@OncoAlert #ESMO26 @kazuki_nozawa
OptiTROP-Lung06:๐ซ
Sac-TMT + pembrolizumab improved median PFS in PD-L1โnegative advanced nonsquamous NSCLC (15.0 vs 5.7 months; HR 0.49), with fewer grade 3 or higher adverse events. OS remains immature; follow-up is key.
@OncoAlert #ESMO26 #LungCancer #ESMOcommunity @myESMO
Original Article: Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1โNegative Advanced NSCLC (phase 3 OptiTROP-Lung06 trial) nej.md/4Bo3liu
#ESMO26 | @myESMO
Beyond Target Loss: T-DXd Resistance
Drug efflux and altered internalization may contribute to resistance, challenging how we approach post-ADC sequencing.
@OncoAlert #ESMO26 #BreastCancer #bcsm #ESMOAmbassadors #ESMOcommunity @myESMO









































